Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Current Deferred Revenue (2021 - 2025)

Roivant Sciences (ROIV) has disclosed Current Deferred Revenue for 4 consecutive years, with $2.7 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Current Deferred Revenue changed N/A year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Jun 2024, changed N/A, and an annual FY2024 reading of $4.2 million, down 66.51% over the prior year.
  • Current Deferred Revenue was $2.7 million for Q2 2024 at Roivant Sciences, down from $4.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $12.4 million in Q1 2023 and bottomed at $2.7 million in Q2 2024.
  • Average Current Deferred Revenue over 4 years is $7.6 million, with a median of $8.1 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue soared 71.46% in 2022, then plummeted 66.51% in 2024.
  • Year by year, Current Deferred Revenue stood at $5.9 million in 2021, then soared by 31.73% to $7.8 million in 2022, then soared by 59.62% to $12.4 million in 2023, then tumbled by 78.62% to $2.7 million in 2024.
  • Business Quant data shows Current Deferred Revenue for ROIV at $2.7 million in Q2 2024, $4.2 million in Q1 2024, and $12.4 million in Q1 2023.